Attached files

file filename
EX-17.1 - EX-17.1 - Redpoint Bio CORPa11-25030_1ex17d1.htm

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): August 25, 2011

 

REDPOINT BIO CORPORATION

 (Exact name of registrant as specified in its charter)

 

Delaware

 

000-51708

 

22-3393959

(State of Incorporation)

 

(Commission File No.)

 

(IRS Employer ID No.)

 

Redpoint Bio Corporation

7 Graphics Drive

Ewing, New Jersey 08628

 (Address of Principal Executive Offices)

 

(609) 637-9700
Registrant’s Telephone Number, Including Area Code:

 

 

 (Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.02.              Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On August 25, 2011, Irwin Scher, M.D., resigned as a member of the Board of Directors (the “Board”) of Redpoint Bio Corporation, a Delaware corporation (the “Company”) and member of the Nominating and Corporate Governance Committee and Intellectual Property Oversight Committee of the Board, effective immediately.  There is no disagreement between Dr. Scher and the Company on any matter relating to the Company’s operations, policies or practices.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

 

Description

17.1

 

Resignation Letter of Irwin Scher, M.D.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

REDPOINT BIO CORPORATION

 

 

Dated: August 26, 2011

 

 

 

 

 

By:

/s/ Scott Horvitz

 

Name:

Scott Horvitz

 

Title:

Chief Financial Officer, Treasurer and Secretary

 

3